Table 5.
Association between patient characteristics and toxicity
| Variable | Patients, n (%) | No grade 3–5 toxicity, n (%) | Grade 3–5 toxicity, n (%) | OR (95% CI) | p value |
|---|---|---|---|---|---|
| Age, years | 1.02 (0.98–1.06) | .376 | |||
| 70 to <78 | 289 (53) | 190 (52) | 99 (56) | ||
| ≥78 | 251 (47) | 174 (48) | 77 (44) | ||
| Sex | 1.35 (0.93–1.95) | .107 | |||
| Male | 333 (62) | 233 (64) | 100 (57) | ||
| Female | 207 (38) | 131 (36) | 76 (43) | ||
| Tumor site | 0.68 (0.31–1.44) | .475 | |||
| GI or GU | 373 (68) | 239 (66) | 121 (69) | ||
| Other | 167 (32) | 125 (34) | 55 (31) | ||
| No. of chemotherapy agents | 0.81 (0.44–1.51) |
.797 |
|||
| Monochemotherapy | 232 (43) | 155 (43) | 77 (44) | ||
| Polychemotherapy | 308 (57) | 209 (57) | 99 (56) | ||
| Chemotherapy dosing | 1.51 (1.04–2.181 |
.028 |
|||
| Standard dose | 301 (56) | 191 (52) | 110 (62) | ||
| Reduced dose | 239 (44) | 173 (48) | 66 (38) | ||
| MAX2 index | |||||
| 0–0.44 | 173 (32) | 109 (30) | 62 (35) | Ref | |
| 0.44–0.57 |
313 (58) |
222 (61) |
91 (52) |
0.81 (0.44–1.52) |
.51 |
| >0.57 | 54 (10) | 33 (9) | 23 (13) | 1.42 (0.95–1.68) | .076 |
| Hemoglobin g/dL | 0.94 (0.84–1.05) | .573 | |||
| ≥10 (female), ≥11 (male) |
416 (77) |
283 (78) |
133 (76) |
||
| <10 (female), <11 (male) | 124 (23) | 81 (22) | 43 (24) | ||
| Albumin g/dL | 0.81 (0.55–1.19) | .315 | |||
| >3.5 | 457 (84) | 312 (86) | 145 (82) | ||
| ≤3.5 | 83 (26) | 52 (14) | 31 (18) | ||
| Creatinine clearance, mL/minute | 0.67 (0.46–0.99) | .031 | |||
| ≥40 | 394 (73) | 276 (76) | 118 (67) | ||
| <40 | 146 (27) | 88 (24) | 58 (33) | ||
| ECOG PS | 1.30 (0.87–1.85) | .236 | |||
| 0 | 133 (25) | 94 (26) | 39 (22) | ||
| ≥1 | 407 (75) | 270 (74) | 137 (78) | ||
| CIRS‐G score | 1.02 (0.89–1.17) | .155 | |||
| No grade 3–4 comorbidity |
336 (62) |
234 (64) |
102 (58) |
||
| Any grade 3–4 comorbidity | 204 (48) | 130 (36) | 74 (42) | ||
| IADL | 0.83 (0.73–0.93) | .034 | |||
| ≥7 | 302 (56) | 215 (59) | 87 (49) | ||
| <7 | 238 (44) | 149 (41) | 89 (51) | ||
| ADL | 0.99 (0.98–1.01) | .286 | |||
| 6 | 334 (62) | 230 (63) | 104 (59) | ||
| ≤5 | 206 (38) | 134 (37) | 72 (41) | ||
| Falls in the past 6 months | 1.11 (0.89–1.42) | .193 | |||
| None | 454 (84) | 308 (85) | 143 (81) | ||
| ≥1 | 86 (16) | 56 (15) | 33 (19) | ||
| SPPB | 1.04 (0.97–1.09) | .669 | |||
| ≥8 | 382 (71) | 251 (69) | 131 (75) | ||
| <8 | 144 (27) | 103 (28) | 41 (23) | ||
| Missing | 14 (3) | 10 (3) | 4 (2) | ||
| Pfeiffer test | 0.67 (0.27–1.32) | .366 | |||
| 0–2 errors | 475 (88) | 317 (87) | 158 (90) | ||
| ≥3 errors | 65 (12) | 47 (13) | 18 (10) | ||
| Hearing | 0.65 (0.42–1.01) | .056 | |||
| Excellent/good | 405 (75) | 264 (73) | 141 (80) | ||
| Fair/poor/deaf | 135 (25) | 100 (27) | 35 (20) | ||
| Medications intake | 0.83 (0.56–1.10) | .332 | |||
| No assistance | 491 (91) | 334 (92) | 157 (89) | ||
| Requires assistance | 49 (9) | 30 (8) | 19 (11) | ||
| MOS Social Support Survey | 0.99 (0.94–1.05) | .256 | |||
| ≤15 | 43 (8) | 25 (7) | 18 (10) | ||
| >15 | 497 (92) | 339 (93) | 158 (90) | ||
| Body mass index, kg/m2 | 1.01 (0.96–1.04) | .898 | |||
| <25 | 223 (41) | 151 (41) | 72 (41) | ||
| ≥25 | 317 (59) | 213 (59) | 104 (59) | ||
| Unintentional weight loss % | 1.02 (0.97–1.06) | .518 | |||
| ≤10% | 438 (81) | 298 (82) | 140 (80) | ||
| >10% | 102 (19) | 66 (18) | 36 (20) | ||
| VES‐13 | 1.54 (1.02–2.06) | .032 | |||
| 0–5 | 425 (79) | 296 (81) | 129 (73) | ||
| >5 | 115 (21) | 68 (19) | 47 (27) |
Bolded values are statistically significant.
Abbreviations: ADL, Activities of Daily Living; CI, confidence interval; CIRS‐G, Cumulative Illness Rating Scale for Geriatrics; ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastrointestinal; GU, genitourinary; IADL, Instrumental Activities of Daily Living; MOS, Medical Outcomes Study; OR, odds ratio; SPPB, Short‐Physical Performance Battery; VES‐13, Vulnerable Elders Survey‐13.